One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Arcutis Biotherapeutics cleared that benchmark Thursday, with a jump from 80 to 85 Thursday.
Looking For The Best Stocks To Buy And Watch? Start Here
This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating of above 80 as they begin their biggest price moves.
Arcutis Biotherapeutics is working on a consolidation with a 17.75 entry. See if it can clear the breakout price in volume at least 40% higher than normal.
The company reported 0% earnings growth in the latest quarterly report, while sales growth came in at 33%.
Arcutis Biotherapeutics holds the No. 57 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
